Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020

Report
229 Pages
November 2020
Region: Global
GlobalData
ID: 5212221

Summary

The publisher's Medical Devices sector report, “Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Ovarian Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Ovarian Cancer Diagnostic Tests include assays of mostly antibodies released in response to a ovarian cancer and cancer-causing proteins.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Ovarian Cancer Diagnostic Tests under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Ovarian Cancer Diagnostic Tests and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment/industry

Reasons to Buy

The report enables you to -

Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of Ovarian Cancer Diagnostic Tests under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date

1 Table of Contents

1.1 List of Tables
1.2 List of Figures
2.1 Ovarian Cancer Diagnostic Tests Overview

3 Products under Development

3.1 Ovarian Cancer - Pipeline Products by Stage of Development
3.2 Ovarian Cancer - Pipeline Products by Territory
3.3 Ovarian Cancer - Pipeline Products by Regulatory Path
3.4 Ovarian Cancer - Pipeline Products by Estimated Approval Date
3.5 Ovarian Cancer - Ongoing Clinical Trials

4 Ovarian Cancer - Pipeline Products under Development by Companies

4.1 Ovarian Cancer Companies - Pipeline Products by Stage of Development
4.2 Ovarian Cancer - Pipeline Products by Stage of Development

5 Ovarian Cancer Companies and Product Overview6 Ovarian Cancer- Recent Developments

7 Appendix

7.1 Methodology
7.2 About the Publisher
7.3 Contact
7.4 Disclaimer

List of Tables

Table 1: Ovarian Cancer - Pipeline Products by Stage of Development
Table 2: Ovarian Cancer - Pipeline Products by Territory
Table 3: Ovarian Cancer - Pipeline Products by Regulatory Path
Table 4: Ovarian Cancer - Pipeline Products by Estimated Approval Date
Table 5: Ovarian Cancer - Ongoing Clinical Trials
Table 6: Ovarian Cancer Companies - Pipeline Products by Stage of Development
Table 7: Ovarian Cancer - Pipeline Products by Stage of Development
Table 8: 2cureX AB Pipeline Products & Ongoing Clinical Trials Overview
Table 9: IndiTreat - OVA - Product Status
Table 10: IndiTreat - OVA - Product Description
Table 11: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 12: Companion Diagnostic Test - Ovarian Cancer - Product Status
Table 13: Companion Diagnostic Test - Ovarian Cancer - Product Description
Table 14: AB ANALITICA srl Pipeline Products & Ongoing Clinical Trials Overview
Table 15: Predictive Biomarker Kit - Ovarian Cancer - Product Status
Table 16: Predictive Biomarker Kit - Ovarian Cancer - Product Description
Table 17: Accudava Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 18: SEPEX - Product Status
Table 19: SEPEX - Product Description
Table 20: SETAX - Product Status
Table 21: SETAX - Product Description
Table 22: Adaptive Biotechnologies Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 23: ImmunoSEQ Dx - Ovarian Cancer - Product Status
Table 24: ImmunoSEQ Dx - Ovarian Cancer - Product Description
Table 25: Almac Diagnostic Services Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 26: ALM AADx Assay - Product Status
Table 27: ALM AADx Assay - Product Description
Table 28: Diagnostic Test - Ovarian Cancer - Product Status
Table 29: Diagnostic Test - Ovarian Cancer - Product Description
Table 30: DNA Damage Response Deficiency Assay - Ovarian Cancer - Product Status
Table 31: DNA Damage Response Deficiency Assay - Ovarian Cancer - Product Description
Table 32: Angle Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 33: Multiplex Ovarian Cancer Biomarker Assay - Product Status
Table 34: Multiplex Ovarian Cancer Biomarker Assay - Product Description
Table 35: Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 36: Cchek - Ovarian Cancer Confirmatory Test - Product Status
Table 37: Cchek - Ovarian Cancer Confirmatory Test - Product Description
Table 38: Cchek - Ovarian Cancer Recurrence Test - Product Status
Table 39: Cchek - Ovarian Cancer Recurrence Test - Product Description
Table 40: Cchek - Ovarian Cancer Screening Test - Product Status
Table 41: Cchek - Ovarian Cancer Screening Test - Product Description
Table 42: Cchek - Ovarian Cancer Treatment Monitoring Test - Product Status
Table 43: Cchek - Ovarian Cancer Treatment Monitoring Test - Product Description
Table 44: Anixa Diagnostics Corporation - Ongoing Clinical Trials Overview
Table 45: Cchek - Ovarian Cancer Screening Test - The Coupling of MDSCs with a Computational Analytic Method to Detect Solid Tumors
Table 46: AroCell AB Pipeline Products & Ongoing Clinical Trials Overview
Table 47: TK 210 Assay - Ovarian Cancer - Product Status
Table 48: TK 210 Assay - Ovarian Cancer - Product Description
Table 49: Arrayit Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 50: Finger Stick Test - Ovarian Cancer - Product Status
Table 51: Finger Stick Test - Ovarian Cancer - Product Description
Table 52: Aspira Labs Pipeline Products & Ongoing Clinical Trials Overview
Table 53: OVA1 Plus Test - Product Status

List of Figures

Figure 1: Ovarian Cancer - Pipeline Products by Stage of Development
Figure 2: Ovarian Cancer - Pipeline Products by Territory
Figure 3: Ovarian Cancer - Pipeline Products by Regulatory Path
Figure 4: Ovarian Cancer - Pipeline Products by Estimated Approval Date
Figure 5: Ovarian Cancer - Ongoing Clinical Trials

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

2cureX AB
A&G Pharmaceutical Inc
AB ANALITICA srl
Accudava Inc
Adaptive Biotechnologies Corp
Almac Diagnostic Services Ltd
Angle Biosciences Inc
Anixa Diagnostics Corporation
AroCell AB
Arrayit Corporation
Aspira Labs
Aurelium BioPharma Inc.
Avant Diagnostics Inc
Ayanda Biosystems SA (Inactive)
BARD1 Life Sciences Ltd
Becton Dickinson and Co
BioFluidica Microtechnologies LLC
Bioindustry Park Silvano Fumero SpA
Brigham and Women's Hospital
Captis Biotechnology Inc
Celcuity Inc
Celula Inc
Ceres Nanosciences Inc
Chronix Biomedical Inc
Clarient Inc
ClavGen Therapeutics LLC
Cleveland Diagnostics Inc.
Courtagen Life Sciences Inc
Dana-Farber Cancer Institute Inc
Diazyme Laboratories Inc
Entopsis LLC
Eventus Diagnostics Inc (Inactive)
Exact Sciences Corp
Exiqon AS
Exosomics Siena SpA
Fahy Gurteen UK Ltd
French National Institute of Health and Medical Research
Ganymed Pharmaceuticals AG
Georgia Institute of Technology
Gina-Life Diagnostics Ltd
GlycoZym USA Inc
H. Lee Moffitt Cancer Center & Research Institute Inc
HealthTell Inc
Hide and Seq
Hudson Institute of Medical Research
Ikonisys Inc
INEX Innovate Pte Ltd
InterGenetics Inc
InterVenn BioSciences
Johns Hopkins University
KIYATEC Inc
Lab Discoveries Ltd
Laboratorios SALVAT SA
Louisville Bioscience Inc (Inactive)
MabCure Inc
Massachusetts Institute of Technology
MDNA Life Sciences Inc
Metabolon Inc
Milagen Inc
MyCartis NV
Nagoya University
Nanostics Inc
Novel Bio-spectrum Technologies Inc (Inactive)
Olink Proteomics AB
Olympia Diagnostics Inc
Oncgnostics GmbH
Oncimmune (USA) LLC
Oncology Venture U.S. Inc
Orion Genomics LLC
OTraces Inc
Peregrine Pharmaceuticals, Inc.
Peri Rx Inc
Precision Biologics Inc
Preora Healthcare Inc
Princess Margaret Cancer Centre
Protagen AG
Proteomika (Inactive)
Provista Diagnostics Inc
Queen's University Belfast
Rosetta Genomics Ltd
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SomaLogic Inc
Soricimed Biopharma Inc
Stage I Diagnostics Inc
StageZero Life Sciences Ltd
SurExam Life Science & Technology Co.
Taizhou ZECEN Biotech Co Ltd
Target Discovery Inc
Teva Pharmaceutical Industries Ltd
The University of Manchester
Tradewind BioScience Inc
Treos Bio Inc
University of Adelaide
University of Arkansas for Medical Sciences
University of California San Diego
University of Chicago
University of Montreal
University of Pittsburgh
University of South Florida
University of Texas MD Anderson Cancer Center
US Biomarkers Inc
Vermillion Inc
Vitruvian Biomedical Inc
Wistar Institute
Yale University
ZORA Biosciences Oy

PURCHASE OPTIONS

Single User License PDF

Site License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3861EUR$4,000USD£3,312GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7722EUR$8,000USD£6,624GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€11582EUR$12,000USD£9,935GBP

Table of Contents

Companies Mentioned (Partial List)

Related Topics

Related Reports

Advanced ovarian cancer - Pipeline Insight, 2024

Epithelial Ovarian Cancer - Pipeline Insight, 2024

Low Grade Serous Ovarian Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033

Ovarian Cancer Opportunity Assessment and Forecast

Ovarian Cancer Diagnostics Global Market Report 2024